Shares in Dublin, Ireland headquartered Perrigo Co. PLC saw a drop of 2.08%, ending Tuesday's trading session at $83.65. The stock recorded a trading volume of 1.21 million shares. The Company's shares have gained 2.07% in the last one month and 0.50% on an YTD basis. The stock is trading 1.94% below its 50-day moving average. Moreover, shares of Perrigo, which together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 47.27.
On January 10th, 2017, Perrigo announced that it has changed its reporting segments. Beginning as of Q4 2016, the Company has the following new reporting segments. Consumer Healthcare Americas comprises the legacy US, Mexico and Canada consumer healthcare business. Consumer Healthcare International comprises the legacy Branded Consumer Healthcare segment and now includes its consumer focused businesses in the UK, Australia and Israel, which were previously reported in the legacy Consumer Healthcare segment. This segment will also include its UK liquids licensed products business. Prescription Pharmaceuticals comprises the legacy US Prescription Pharmaceuticals business. Specialty Sciences will continue to comprise royalties from Tysabri®. Other will continue to comprise the legacy Active Pharmaceutical Ingredients business. Your complete research report on PRGO can be retrieved for free at:
Billerica, Massachusetts headquartered Bruker Corp.'s stock rose 3.14%, closing the day at $22.98. A total volume of 939,347 shares was traded, which was above their three months average volume of 715,620 shares. The Company's shares have advanced 5.46% in the last month, 4.31% over the previous three months, and 8.50% since the start of this year. The stock is trading 4.62% above its 50-day moving average. Additionally, shares of Bruker, which together with its subsidiaries, designs and manufactures scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 64.86.
On January 04th, 2017, Bruker announced the acquisition of SCiLS GmbH in Bremen, Germany. SCiLS develops innovative software tools such as statistical analysis software, sophisticated visualization viewers, and secure cloud-based services for collaborative interpretation of complex mass spectrometry imaging data sets. Financial details were not disclosed.
On January 04th, 2017, research firm Barclays downgraded the Company's stock rating from 'Overweight' to 'Equal Weight' while revising its previous target price from $30 a share to $22 a share. BRKR free report is just a click away at:
On Tuesday, shares in Dublin, Ireland headquartered ICON PLC recorded a trading volume of 756,200 shares, which was higher than their three months average volume of 467,640 shares. The stock ended the day 1.98% higher at $81.96. The Company's shares have advanced 7.15% in the past month, 3.72% in the previous three months, and 8.99% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.41% and 10.95%, respectively. Furthermore, shares of ICON, which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the US, and internationally, have an RSI of 67.20.
On December 16th, 2016, research firm Goldman upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On January 09th, 2017, ICON announced its financial guidance for FY17. The Company expects revenue to be in the range of $1.70 billion - $1.75 billion for FY17 and earnings per share to be in the band of $5.00 - $5.20 for FY17. Sign up for your complimentary research report on ICLR at:
HTG Molecular Diagnostics
Tucson, Arizona-based HTG Molecular Diagnostics Inc.'s stock dropped 2.29%, finishing yesterday's session at $2.13 with a total trading volume of 18,379 shares. The Company's shares are trading above their 50-day moving average by 2.16%. Shares of the Company, which develops and markets technology platforms that facilitate the routine use of complex molecular profiling, have an RSI of 50.92.
On January 05th, 2017, HTG Molecular announced that it has submitted to the FDA the third of four expected modules for the Company's Pre-Market Approval (PMA) application for the HTG EdgeSeq ALKPlus Assay to be used as a companion diagnostic for Crizotinib. The third PMA module included data from analytical performance studies completed at HTG along with inter-lab reproducibility study data completed at three trial sites. Register for free on Stock-Callers.com and download the latest research report on HTGM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA